(marketscreener.com) 20 December 2021. Telix Pharmaceuticals Limited , a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on molecularly targeted radiation , today announces that the United States Food and Drug Administration has approved Telix’s lead prostate cancer imaging product, Illuccix®.
Source
We have spent countless hours researching companies that have acted against their clients based on their political beliefs. Your donation allows us to continue to work on and share our lists to support our Free Market Economy.
Help contribute to our research, and let us know if you have seen similar situations that we may have missed. Our team will review the details you provide and add to our main list once we verify the information.
Get notified when we release our updated lists by email.
We will send you an email to confirm your details. Welcome aboard!
We will review your information, and publish in on our list once we validate the details.
